Terrance Mcguire Sells 75,776 Shares of Invivyd, Inc. (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 75,776 shares of the stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $0.45, for a total value of $34,099.20. Following the completion of the transaction, the director now owns 3,492,498 shares of the company’s stock, valued at $1,571,624.10. This trade represents a 2.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Terrance Mcguire also recently made the following trade(s):

• On Thursday, December 26th, Terrance Mcguire sold 83,817 shares of Invivyd stock. The stock was sold at an average price of $0.54, for a total transaction of $45,261.18.
• On Friday, December 20th, Terrance Mcguire sold 119,805 shares of Invivyd stock. The shares were sold at an average price of $0.42, for a total transaction of $50,318.10.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total value of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The stock was sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Price Performance

NASDAQ:IVVD traded up $0.02 during midday trading on Thursday, reaching $0.53. The stock had a trading volume of 870,708 shares, compared to its average volume of 667,876. The stock has a market capitalization of $63.44 million, a P/E ratio of -0.27 and a beta of 0.53. Invivyd, Inc. has a 1-year low of $0.40 and a 1-year high of $5.20. The firm’s fifty day simple moving average is $0.74 and its 200-day simple moving average is $0.99.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Morgan Stanley reduced their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. HC Wainwright reduced their price objective on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, D. Boral Capital reiterated a “buy” rating and set a $9.00 price target on shares of Invivyd in a research note on Thursday, November 21st. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Invivyd presently has an average rating of “Buy” and a consensus price target of $7.89.

Institutional Investors Weigh In On Invivyd

Hedge funds and other institutional investors have recently made changes to their positions in the business. Proficio Capital Partners LLC bought a new stake in Invivyd during the 3rd quarter valued at approximately $27,000. XTX Topco Ltd grew its stake in shares of Invivyd by 68.1% in the second quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after acquiring an additional 15,376 shares during the last quarter. SG Americas Securities LLC increased its position in Invivyd by 198.6% during the second quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after acquiring an additional 25,201 shares during the period. Cornercap Investment Counsel Inc. acquired a new position in Invivyd during the 2nd quarter valued at $86,000. Finally, Rhumbline Advisers boosted its holdings in Invivyd by 4,434.1% in the 2nd quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock valued at $92,000 after purchasing an additional 82,164 shares during the period. 70.36% of the stock is owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.